Paul Allen-backed BiPar Sciences sells out for $500 million |
Connect with TechFlash on our Facebook page for all the latest technology news headlines and commentary, plus information and access to special events, photos from events, promotions and more.
Today On Techflash
- Amazon falls on world's most valuable brand list; Microsoft at No. 5
- Amazon announces deal with Paramount Pictures
- Group plans protest at Amazon shareholder meeting
- Seattle webcomic The Oatmeal generates Tesla-Edison controversy
- Amazon shareholders met by protesters, company cuts ties with ALEC
- Microsoft Windows Phone tops Apple's iPhone in China
Mass High Tech
Paul Allen-backed BiPar Sciences sells out for $500 million
It's been a rough ride for Microsoft billionaire Paul Allen so far this year, with his cable company, Charter Communications, filing for bankruptcy and his private investment firm, Vulcan, conducting layoffs. But Allen got a dose of good news today when Sanofi-aventis announced it was buying biotechnology company BiPar Sciences for up to $500 million. It's a hefty return for Vulcan, which led the series A deal four years ago.
BiPar is developing a new way to destroy cancer cells using what are known as PARP inhibitors, which prevent the cells from repairing their own DNA. The Brisbane, Calif.-based company's lead product -- for breast cancer -- is currently in Phase 2 trials.
Vulcan led the first $13 million investment in the company in late 2004, which was followed by capital from Domain Associates and Canaan Partners. BiPar raised a $20 million round in January.
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
